Cancer Vaccine Breakthrough: COVID-19 Tech Targets Root Mutations for Lung Cancer Prevention

In a significant leap forward for oncology, researchers are leveraging the groundbreaking mRNA technology behind COVID-19 vaccines to develop innovative cancer vaccines. This new wave of treatment focuses on targeting the fundamental 'root mutations' within cancer cells, akin to addressing the source of a problem rather than just its symptoms. Medical Oncology Specialist Assoc. Prof. Dr. Ferhat Ferhatoğlu explains that this approach draws parallels to biological evolution, where mutations drive the emergence of new species, and cancer similarly progresses through a dynamic, branching process.

“

This situation causes cancer cells to acquire different characteristics over time. We can liken this process to biological evolution. Just as mutations lead to the emergence of new species, cancer is a similarly branching, dynamic process.

The development of cancer vaccines has become a focal point of immunotherapy in recent years. These vaccines are broadly categorized into preventive ones, like those against HPV and HBV, and therapeutic vaccines designed to directly combat cancer cells. The therapeutic vaccines work by activating the immune system to eliminate cancerous cells. However, the novel approach discussed here offers a deeper insight into the nature of cancer itself, aiming to neutralize the disease before it can fully establish resistance.

“

Cancer vaccines are one of the most notable areas of immunotherapy in recent years.

Assoc. Prof. Dr. Ferhatoğlu highlights that the genetic diversity among tumor cells allows them to adapt to changing environments and develop resistance to treatments like chemotherapy, radiotherapy, and surgery. Cells that survive initial treatments can proliferate and become more resilient, necessitating more targeted strategies. The new approach seeks to identify and target the 'trunk' mutations—those common to all cancer cells—thereby preventing the cancer from forming in the first place. This strategy holds particular promise for individuals at high risk, especially for lung cancer.

“

If we can detect these root mutations, it may be possible to prevent cancer before it even forms by stimulating the immune system against these targets.

The TRACERx study, initiated in 2014, provided crucial evidence that cancer evolves like an 'evolutionary tree,' revealing the existence of root mutations common to all tumor cells. These findings have laid the groundwork for the development of LungVax, the first lung cancer vaccine for high-risk individuals. The LungVax trial, to be conducted in Oxford, aims to prevent the recurrence of cancer in patients who have undergone surgery for early-stage non-small cell lung cancer. By targeting common neoantigens, the vaccine seeks to generate a robust immune response, eliminating cancer cells before they become clinically apparent.

“

This vaccine aims to create a strong immune response by targeting common neoantigens in tumors. Thus, cancer cells can be eliminated before they become clinically apparent.